$Zura Bio (ZURA.US)$ Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
$Zura Bio (ZURA.US)$Zura Bio Ltd: Tibulizumab (Zb-106) Was Well Tolerated and Neutralized Il-17a and Baff in a Phase 1 Study in Patients With Sjogren's Syndrome! Presents data at EULAR 2024
SniperInWood
:
lol not confuse they work both ways wild short selling in negative outlook and going long side wild upwing on positive outlook about any company , they are market makers they also go wrong anytime not 101% right ,aim small never be overconfident on their ratings
$Zura Bio (ZURA.US)$ Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024 Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...
Zura Bio Garners Enthusiastic Ratings from Analysts with a Bright Outlook. Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler und...
$Zura Bio (ZURA.US)$SC 13G: Statement of acquisition of beneficial ownership by individuals-Venrock Healthcare Capital Partners III, L.P.(9.99%),VHCP Co-Investment Holdings III, LLC(9.99%), etc. SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.1%),Peter Kolchinsky(5.1%), etc.
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Zura Bio Stock Forum
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...
Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler und...
SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.1%),Peter Kolchinsky(5.1%), etc.
NEWS
Zura Bio Raises $112.5M Through Private Placement Deal
NEWS
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
No comment yet